| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/02/2005 | US20050120409 Expression vector comprising nucleotide sequences coding hypersensitive response eliciting protein for use in generating disease, insect, drought and heat resistant plants; biological pest control |
| 06/02/2005 | US20050120400 Genetically engineered, galactosyltransferase deficient, pigs for use as source of organs, tissues and cells for xenotransplantation |
| 06/02/2005 | US20050119472 GB virus C and methods of treating viral infections |
| 06/02/2005 | US20050119458 Transport protein for use in identifying modulator for prevention and treatment of cell proliferative, skin and psychological disorders; anticonvulsants; insecticides; pesticides; anthelmintics |
| 06/02/2005 | US20050119457 Human proteins |
| 06/02/2005 | US20050119216 Pharmaceutical compositions and methods relating to fucans |
| 06/02/2005 | US20050119214 Nuclease resistant double-stranded ribonucleic acid |
| 06/02/2005 | US20050119213 Vascular therapeutics |
| 06/02/2005 | US20050119210 Using genes encoding transmembrane protein as markers; targets for cancer therapy; drug screening |
| 06/02/2005 | US20050119208 Composition and method for treating lupus nephritis |
| 06/02/2005 | US20050119206 Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis |
| 06/02/2005 | US20050119205 Methods of modulating heme oxygenase-1 expression and treating heme oxygenase-1 mediated conditions |
| 06/02/2005 | US20050119204 Osteopontin-related compositions and methods |
| 06/02/2005 | US20050119201 Inhibitor of dna methylation |
| 06/02/2005 | US20050118718 Stabilization and controlled delivery of ionic biopharmaceuticals |
| 06/02/2005 | US20050118701 Large scale methods of producing adenovirus and adenovirus seed stocks |
| 06/02/2005 | US20050118699 Packaging complementation cell-line for sv-40 vectors |
| 06/02/2005 | US20050118684 Recombinant antihemophilic factor for use as tool in treatment hemophilia |
| 06/02/2005 | US20050118681 Transcription factor for use as regulatory tool in expression of musculin; treatment and prevention of myogenic cancers |
| 06/02/2005 | US20050118656 Methods for diagnosis and treatment of epithelial-derived cancers |
| 06/02/2005 | US20050118629 antibody to polypeptide containing a fragment capable of binding to and inducing apoptosis in a carcinoma cell; Tumor Necrosis Factor Related ligand or "TRELL", a polypeptide which is a member of the Tumor Necrosis Factor Family |
| 06/02/2005 | US20050118606 Methods for identifying risk of breast cancer and treatments thereof |
| 06/02/2005 | US20050118605 RNA-induced silencing complexes; RNA interference; gene expression inhibition |
| 06/02/2005 | US20050118586 Expression vector comprising nucleotide sequences coding heterologous polypeptide for use in forensic analysis as chromosome, tissue, cell and organelle specific markers |
| 06/02/2005 | US20050118573 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses |
| 06/02/2005 | US20050118567 Method for determining sensitivity to a bacteriophage |
| 06/02/2005 | US20050118253 comprising a nucleic acid that is fully encapsulated within a lipid; for treating a neoplasia in a mammal |
| 06/02/2005 | US20050118206 A surfactant, a solvent, and a beneficial agent; exposure to a hydrophilic environment, surfactant and solvent form a viscous gel and beneficial agent dispersed or dissolved in the gel; |
| 06/02/2005 | US20050118195 Virus causing respiratory tract illness in susceptible mammals |
| 06/02/2005 | US20050118193 Live, attenuated, invasive bacterium that infects a mammalian host cell, and releases exogenous RNA into the cytoplasm of the host cell; can express e.g. immunogens, ribozymes; vaccines, cancer or viral disease treatment via gene expression inhibition |
| 06/02/2005 | US20050118192 Viral preparations, vectors, immunogens, and vaccines |
| 06/02/2005 | US20050118186 Treating ovarian or colorectal cancer by immunizing against the tumor rejection antigen PRAME and other tumor-associated antigen(s) such as NY-ESO-1 also known as CTAG-1 (Cancer-Testis Antigen-1) and SSX-2, also known as Hom-Mel-40 a cancer-testis antigen |
| 06/02/2005 | US20050118178 Use of t-cell immune response cdna7 (tirc7) in angiogenic and anti-angiogenic therapy |
| 06/02/2005 | US20050118177 Method for the improvement of neuronal regeneration |
| 06/02/2005 | US20050118160 Inhibits delayed vascular rejection; makes organs less vulnerable to rejection after transplantation |
| 06/02/2005 | US20050118157 Treatment of central nervous system damage |
| 06/02/2005 | US20050118151 Drug screening; proteins that can be used as targets for the treatment of diabetes |
| 06/02/2005 | US20050118150 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine |
| 06/02/2005 | US20050118148 Compositions and methods related to mammalian Maf-A |
| 06/02/2005 | US20050118141 Transplantable lung carcinoma xenograft useful in experimental models of carcinoma in order to dissect out the molecular basis of the phenotype; the model of carcinoma can be used to identify molecular targets, assess the efficacy of theraputic agents |
| 06/02/2005 | US20050118140 Madin Darby Canine Kidney cells are virally infected and cultured in suspension on an industrial scale to produce the active ingredient, and then mixed with a carrier or dilluent |
| 06/02/2005 | US20050118139 Canine papillomavirus E genes are codon-optimized to enhance expression in host cells; the vector is an adenovirus vector or a plasmid vector, and the genes are from a human papillomavirus serotype; prevention and prophylaxis |
| 06/02/2005 | US20050118117 Methods for identifying risk of melanoma and treatments thereof |
| 06/02/2005 | DE10350256A1 PIM-1-spezifische siRNA-Verbindungen PIM-1 specific siRNA compounds |
| 06/02/2005 | CA2547079A1 Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases |
| 06/02/2005 | CA2546860A1 Ocular tissue modification |
| 06/02/2005 | CA2546074A1 Syk-targeted nucleic acid interference |
| 06/02/2005 | CA2546067A1 Fcyriia-specific nucleic acid interference |
| 06/02/2005 | CA2545944A1 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
| 06/02/2005 | CA2545915A1 Minimization of drug oxidation in drug irradiated excipients formulations |
| 06/02/2005 | CA2545800A1 Surfactant-based gel as an injectable, sustained drug delivery vehicle |
| 06/02/2005 | CA2545049A1 Method for proliferating cardiomyocytes |
| 06/02/2005 | CA2543072A1 Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens |
| 06/02/2005 | CA2526860A1 Synthetic mammalian retrotransposon gene |
| 06/02/2005 | CA2515890A1 Novel insertion sites in pox vectors |
| 06/01/2005 | EP1536015A1 Promoters for expression in modified vaccinia virus ankara |
| 06/01/2005 | EP1536010A1 Preventives/remedies for cancer |
| 06/01/2005 | EP1536007A1 Artificial mammalian chromosome |
| 06/01/2005 | EP1535995A1 Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof |
| 06/01/2005 | EP1535993A1 Biomolecule transfer method using virus envelope and composition and system therefor |
| 06/01/2005 | EP1535067A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE |
| 06/01/2005 | EP1534861A1 Sirna-mediated gene silencing with viral vectors |
| 06/01/2005 | EP1534847A1 Retroviral vector and stable packaging cell lines |
| 06/01/2005 | EP1534839A1 Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression |
| 06/01/2005 | EP1534820A2 Ex-vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures |
| 06/01/2005 | EP1534747A2 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications |
| 06/01/2005 | EP1534736A2 Nogo receptor antagonists |
| 06/01/2005 | EP1534731A1 Bmp-2 estrogen responsive element and methods of using the same |
| 06/01/2005 | EP1534728A2 Antisense modulation of glucocorticoid receptor expression |
| 06/01/2005 | EP1534658A2 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 06/01/2005 | EP1534345A2 Method and device for inducing biological processes by micro-organs |
| 06/01/2005 | EP1534344A2 Viruses and virus-like particles for multiple antigen and target display |
| 06/01/2005 | EP1534331A2 Membrane associated tumor endothelium markers |
| 06/01/2005 | EP1534328A2 Protective antigens for the control of ixodes species infestations |
| 06/01/2005 | EP1534312A2 Intrathecal and intratumoral superantigens to treat malignant disease |
| 06/01/2005 | EP1534308A2 Peptides with growth inhibitory action |
| 06/01/2005 | EP1534306A2 Defensins: use as antiviral agents |
| 06/01/2005 | EP1119346B1 Rna cancer vaccine and methods for its use |
| 06/01/2005 | EP1100878B1 Process for producing genetically modified cd34-negative adherently growing haematopoietic stem cells |
| 06/01/2005 | EP0954573B1 Preparation of ionically cross-linked polyphosphazene microspheres by coacervation |
| 06/01/2005 | EP0792358B1 A polynucleotide tuberculosis vaccine |
| 06/01/2005 | EP0769059B1 Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms |
| 06/01/2005 | CN1623001A System for monitoring bacterial tumor treatment |
| 06/01/2005 | CN1622995A Receptor nucleic acids and polypeptides |
| 06/01/2005 | CN1622994A TGF-beta-specific covalently closed antisense molecule |
| 06/01/2005 | CN1622957A IFNAR2 mutants, their production and use |
| 06/01/2005 | CN1622956A Cytotoxic cyplasin of the sea hare, aplysia punctata, cdna cloning and expression of bioreactive recombinants |
| 06/01/2005 | CN1622831A Method of promoting nucleic acid transfer |
| 06/01/2005 | CN1621414A Antigenic determinant polypeptide of human tumor-testis antigen HCA587 and use thereof |
| 06/01/2005 | CN1621094A Gene transfer for regulating smooth muscle tone |
| 06/01/2005 | CN1204253C Neisseria lactoferrin binding protein |
| 06/01/2005 | CN1204142C Antigene V-erb B oligonucleotide and its use |
| 06/01/2005 | CN1203847C Chemically-defined non-polymeric valency plateform molecules and conjugates thereof |
| 05/31/2005 | US6900367 Transgenic Drosophila melanogaster expressing a β42 in the eye |
| 05/31/2005 | US6900299 Antisense oligonucleotide inhalant for prevention and treatment of respiratory system disorders; viricides |
| 05/31/2005 | US6900297 A compound which hybridizes with a nucleic acid includes multiple inked nucleosides (inlcudes a pentofuranosyl sugar portion and a base portion), and at least one sugar o-is terminated with R-N(R1a R1b) substitutent |
| 05/31/2005 | US6900288 Comprises membrane glycoproteins for diagnosis, prevention and treatment of nervous system and cell proliferative disorders |
| 05/31/2005 | US6900187 TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| 05/31/2005 | US6900185 Genetic engineering; binding Dna to apolipoprotein ligand; antitumor agents |
| 05/31/2005 | US6900177 Anticholesterol agents; cardiovascular disorders |